Antoine Papiernik

So I'm not going to comment more than that.

But seeing it is amazing.

Well, outside of share price, and this is not Adivac related, it's what I've been doing for 30 years and need to recognize that that's a place where we have a lot of progress to do.

So can you rate $750 million, I think, plus the green shoe, I think it was even higher than that, $800 million on the basis of any results?

in Europe in a biotech company?

The answer is clear cut, has never been done.

Can it be done?

Well, you know, so probably not in my lifetime.

So I hope it could.

I think, you know, since the beginning of my career, there was, you know, EASDAQ and all this idea that we would get there and have our own NASDAQ and look what happened.

So today, the answer to your question, I'm afraid, is no.

And we need to, you know, I don't have the time and my LPs don't have the time to wait for it.

So we need to do what we need to do.

And if we need to bring our companies to Nasdaq, they still, you know, it's a, you know, Abivax is a Paris-based company.

In fact, it's in our own, in the same building as Sofinova on the third floor.

We're on the seventh floor.

So just to tell you, it couldn't be closer to us in Paris.

And yet it is a, you know, very large now market cap company based on the results that they've had.

No, I think it's not about what your passport says.

It's about what competence you have and how you can demonstrate this to your investor base.